New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 5, 2014
07:00 EDTFURX, SLXPFurex drug should not be seen as threat to Salix, says Piper Jaffray
Piper Jaffray believes Furiex's (FURX) receptor antagonist eluxadoline in diarrhea-predominant irritable bowel syndrome should not be seen as a threat to Salix's (SLXP) Xifaxan in IBS-D. Piper says eluxdaoline and Xifaxan are mechanistically very different and will be used differently. The firm views Salix as attractive and reiterates an Overweight rating on the stock with a $106 price target.
News For SLXP;FURX From The Last 14 Days
Check below for free stories on SLXP;FURX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 23, 2014
10:02 EDTSLXPOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:10 EDTSLXPDeutsche Bank hosts an analyst Specialty Pharma/Industry conference call
Subscribe for More Information
July 22, 2014
16:08 EDTSLXPSalix initiated with a Hold at Deutsche Bank
Subscribe for More Information
July 17, 2014
05:24 EDTSLXPSalix, Pharming Group announces FDA approval of Ruconest
Subscribe for More Information
July 16, 2014
09:12 EDTSLXPLeerink healthcare analyst holds an analyst/industry conference call
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use